Thalomid Dispensing Authorization Guidelines

Dispensing prescriptions for Thalomid involves an authorization process from its manufacturer, the Celgene Corporation. This process is standardized throughout the United States.

The medication has significant benefits, yet it also has serious potential side effects.

Once a pharmacy technician receives a prescription for the medication, he or she must call the Celgene Corporation and go through an authorization process.

Once the technician has received authorization, there is only a short window of time allowed to dispense the medication.

Authorization can be obtained either by speaking with a representative or through Celgene's automated telephone authorization process.

What is it prescribed for?

According to the Celgene website, it is prescribed for the treatment of Multiple Myeloma and Erythema Nodosum Leprosum.

What are these two conditions?

According to Wikipedia, Multiple Myeloma (MM) "is a type of cancer of plasma cells which are immune system cells in bone marrow that produce antibodies." The medical community considers Multiple Myeloma incurable. However, stem cell transplants, antineoplastic drug treatment (or chemotherapy), treatment with steroids, or treatment with this medication may bring on a remission.

According to The Free Dictionary Erythema Nodosum Leprosum is "an inflammatory complication of leprosy that results in painful skin lesions on the arms and legs and face."

Top of Thalomid Page

Back to Prescription Authorization Page

Back to Home Page